A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

284

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

COMBINATION_PRODUCT: ofatumumab with PRF
COMBINATION_PRODUCT: ofatumumab with AI

Sponsor

Novartis Pharmaceuticals